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A genetic component influences the development of atherosclerosis in the general population and 
also in rheumatoid arthritis (RA). However, genetic polymorphisms associated with atherosclerosis in 
the general population are not always involved in the development of cardiovascular disease (CVD) in 
RA. Accordingly, a study in North-American RA patients did not show the association reported in the 
general population of coronary artery disease with a series of relevant polymorphisms (TCF21, LPA, 
HHIPL1, RASD1-PEMT, MRPS6, CYP17A1-CNNM2-NT5C2, SMG6-SRR, PHACTR1, WDR12 and COL4A1-
COL4A2). In the present study, we assessed the potential association of these polymorphisms with CVD 
in Southern European RA patients. We also assessed if polymorphisms implicated in the increased risk of 
subclinical atherosclerosis in non-rheumatic Caucasians (ZHX2, PINX1, SLC17A4, LRIG1 and LDLR) may 
influence the risk for CVD in RA. 2,609 Spanish patients were genotyped by TaqMan assays. Subclinical 
atherosclerosis was determined in 1,258 of them by carotid ultrasonography (assessment of carotid 
intima media thickness and presence/absence of carotid plaques). No statistically significant differences 
were found when each polymorphism was assessed according to the presence/absence of cardiovascular 
events and subclinical atherosclerosis, after adjustment for potential confounder factors. Our results do 
not show an association between these 15 polymorphisms and atherosclerosis in RA.
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A genetic component influences the development of atherosclerosis in the general population and also in patients 
with rheumatoid arthritis (RA)1,2. Several pieces of evidence support the hypothesis that both pathologies share 
many similarities and exhibit analogous pathophysiological mechanisms3. However, genetic polymorphisms 
associated with atherosclerosis in the general population are not always involved in the development of cardiovas-
cular disease (CVD) in RA2. In this respect, a recent study performed in patients with RA from North-America 
did not disclose that a series of gene polymorphisms related to coronary artery disease in the general population4 
were involved in the development of atherosclerotic disease in RA5. This study included, among others, the fol-
lowing polymorphisms: TCF21 [transcription factor 21] rs12190287, LPA [lipoprotein, Lp[a]] rs3798220, HHIPL1 
[Hedgehog interacting protein-like protein 1] rs2895811, RASD1 [RAS dexamethasone-induced 1]-PEMT [phos-
phatidylethanolamine N-methyltransferase] rs12936587, MRPS6 [mitocondrial ribosomal protein S6] rs9982601, 
CYP17A1 [Cytochrome P450, Family 17, Subfamily A, Polypeptide 1]-CNNM2 [Cyclin and CBS domain divalent 
metal cation transport mediator 2]-NT5C2 [5′ -nucleotidase, cytosolic II] rs12413409, SMG6 [SMG6 nonsense 
mediated mRNA decay factor]-SRR [serine racemase] rs216172, PHACTR1 [phosphatase and actin regulator 1] 
rs12526453, WDR12 [WD repeat domain 12] rs6725887 and COL4A1-COL4A2 [collagen type IV alpha 1- collagen 
type IV alpha 2] rs47731445.
In the present study, we assessed the potential association of these polymorphisms with CVD in Southern 
European individuals with RA. Moreover, we also assessed if other gene polymorphisms implicated in the 
increased risk of subclinical atherosclerosis in non-rheumatic Caucasian individuals6 may influence the risk for 
CVD in RA. These polymorphisms associated with subclinical atherosclerosis in the general population were 
the following: ZHX2 [zinc fingers and homeoboxes 2] rs11781551, PINX1 [Pin2-interacting protein] rs6601530 
and SLC17A4 [solute carrier family 17, member 4] rs4712972 as significant signals associated with carotid 
intima-media thickness (cIMT) and LRIG1 [leucine-rich repeats and immunoglobulin-like domains 1] rs17045031 
and LDLR [low density lipoprotein receptor] rs6511720 as relevant polymorphisms involved in the presence of 
carotid plaques6.
Patients and Methods
Patients and Study Protocol. A set of 2,609 unrelated Spanish RA patients fulfilling the 2010 American 
College of Rheumatology classification criteria for RA7 was included in our study. Blood samples were obtained 
from patients recruited from Hospital Lucus Augusti (Lugo), Marqués de Valdecilla (Santander), Bellvitge 
(Barcelona), San Cecilio (Granada), Canarias (Tenerife), Doctor Peset (Valencia), General de Ciudad Real 
(Ciudad Real) and Clínico San Carlos, La Paz, La Princesa, Gregorio Marañón and 12 de Octubre (Madrid). This 
cohort included patients with RA from all parts of Spain. For this purpose, only native Spaniards were included 
and individuals with RA of different genetic backgrounds such as South Americans, black people or other indi-
viduals from different parts of the world were excluded from the analysis.
For experiments involving humans and the use of human blood samples, all the methods were carried out in 
accordance with the approved guidelines and regulations, according to the Declaration of Helsinki. All exper-
imental protocols were approved by the Ethics Committees of clinical research of Galicia for Hospital Lucus 
Augusti in Lugo, of Cantabria for Hospital Marqués de Valdecilla in Santander, of Cataluña for Hospital de 
Bellvitge in Barcelona, of Andalucía for Hospital San Cecilio in Granada, of Canarias for Hospital de Canarias 
in Tenerife, of Comunidad Valenciana for Hospital Doctor Peset in Valencia, of Castilla-La Mancha for Hospital 
General de Ciudad Real in Ciudad Real and of Madrid for Hospital Clínico San Carlos, La Paz, La Princesa, 
Gregorio Marañón and 12 de Octubre in Madrid. Informed consent was obtained from all subjects.
Epidemiological and clinical characteristics of patients enrolled in the study are shown in Table 1. Definitions 
of cardiovascular (CV) events and for traditional CV risk factors were established as previously described8.
Genotyping. DNA from patients was obtained from peripheral blood using standard methods.
For the selection of the gene polymorphisms studied in the present report, we carried out a search of 
genes associated with CVD or subclinical atherosclerosis in the general population. Based on this analy-
sis, TCF21 rs12190287, LPA rs3798220, HHIPL1 rs2895811, RASD1-PEMT rs12936587, MRPS6 rs9982601, 
CYP17A1-CNNM2-NT5C2 rs12413409, SMG6-SRR rs216172, PHACTR1 rs12526453, WDR12 rs6725887, 
COL4A1-COL4A2 rs4773144, ZHX2 rs11781551, PINX1 rs6601530, SLC17A4 rs4712972, LRIG1 rs17045031 and 
LDLR rs6511720 were assessed in patients with RA. For this purpose, a TaqMan predesigned single-nucleotide 
polymorphism genotyping assays in a 7900 HT Real-Time polymerase chain reaction (PCR) system, according to 
the conditions recommended by the manufacturer (Applied Biosystems, Foster City, CA, USA), was performed.
Negative controls and duplicate samples were included to check the accuracy of genotyping.
Carotid ultrasonography (US) examination. cIMT values and presence/absence of carotid plaques 
were evaluated in 1,258 cases. Patients from Santander, Granada, Tenerife, Valencia, Ciudad Real and Madrid 
were assessed using a commercially available scanner, Mylab 70, Esaote (Genoa, Italy)9. Patients from Lugo were 
assessed using high-resolution B-mode ultrasound, Hewlett Packard SONOS 55008. cIMT was measured at the 
far wall of the right and left common carotid arteries, 10 mm from the carotid bifurcation, over the proximal 
15 mm-long segment. cIMT value was determined as the average of three measurements in each common carotid 
artery. The final cIMT was the largest average cIMT (left or right)9,10. The plaque criteria in the accessible extrac-
ranial carotid tree were focal protrusion in the lumen at least cIMT > 1.5 mm, protrusion at least 50% greater than 
the surrounding cIMT, or arterial lumen encroaching > 0.5 mm10,11. Agreement between these two US methods 
was previously reported12. Experts with a high reproducibility, excellent inter-observer reliability and close col-
laboration in the assessment of subclinical atherosclerosis in RA performed the studies.
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Statistical analysis. Genotype data were checked for deviation from Hardy-Weinberg equilibrium (HWE) 
using http://ihg.gsf.de/cgi-bin/hw/hwa1.pl.
Power for the study was calculated using “CaTS-Power Calculator for Two Stage Association Studies” (http://
www.sph.umich.edu/csg/abecasis/CaTS/).
The relationship between allelic frequencies and the presence/absence of CV events was tested using logistic 
regression adjusting for sex, age at RA diagnosis, follow-up time and traditional CV risk factors as potential con-
founder factors. Results were expressed as odds ratios (OR) with 95% confidence intervals (CI).
Association between allelic frequencies and cIMT values was tested using unpaired t test. Results were 
adjusted for sex, age at the time of US study, follow-up time and traditional CV risk factors as potential con-
founder factors using analysis of covariance (ANCOVA).
Differences in the allelic frequencies according to the presence/absence of carotid plaques were calculated by 
χ 2 or Fisher tests. Strength of associations was estimated using OR and 95% CI. Results were adjusted for sex, age 
at the time of US study, follow-up time and traditional CV risk factors as potential confounder factors by logistic 
regression.
Analyses were performed with STATA statistical software 12/SE (Stata Corp., College Station, TX, USA).
Results
Polymorphisms genotyped were in HWE and genotyping success was > 99%.
The study had ≥ 90% of power to detect genotypic OR = 1.3 for TCF21 rs12190287, HHIPL1 rs2895811, 
RASD1-PEMT rs12936587, SMG6-SRR rs216172, PHACTR1 rs12526453, COL4A1-COL4A2 rs4773144, ZHX2 
rs11781551 and PINX1 rs6601530, and ≥ 90% to detect OR ≥ 1.4 for LPA rs3798220, MRPS6 rs9982601, 
CYP17A1-CNNM2-NT5C2 rs12413409, WDR12 rs6725887, SLC17A4 rs4712972, LRIG1 rs17045031 and LDLR 
rs6511720.
Influence of TCF21, LPA, HHIPL1, RASD1-PEMT, MRPS6, CYP17A1-CNNM2-NT5C2, SMG6-SRR, 
PHACTR1, WDR12 and COL4A1-COL4A2 polymorphisms on CV events or subclinical 
atherosclerosis in patients with RA. Firstly, we assessed the potential influence of TCF21 rs12190287, 
LPA rs3798220, HHIPL1 rs2895811, RASD1-PEMT rs12936587, MRPS6 rs9982601, CYP17A1-CNNM2-NT5C2 
rs12413409, SMG6-SRR rs216172, PHACTR1 rs12526453, WDR12 rs6725887 and COL4A1-COL4A2 rs4773144 
on the risk of CV events or subclinical atherosclerosis in RA patients (Table 2). In this sense, no statistically sig-
nificant differences were found when each polymorphism was assessed according to the presence/absence of CV 
events after adjustment of the results for potential confounder factors. Similarly, no statistically significant dif-
ferences were detected when each polymorphism was evaluated according to the cIMT values and the presence/
absence of carotid plaques in RA patients, even after adjustment (Table 2).
Influence of ZHX2, PINX1, SLC17A4, LRIG1 and LDLR polymorphisms on CV events or subclinical 
atherosclerosis in patients with RA. Subsequently, we evaluated the potential relationship between 
ZHX2 rs11781551, PINX1 rs6601530, SLC17A4 rs4712972, LRIG1 rs17045031 and LDLR rs6511720 and CV 
Clinical Feature % (n/N)
Age at the time of disease onset (years, 
mean ± standard deviation) 50.8 ± 14.7
Follow-up (years, mean ± standard 
deviation) 12.7 ± 8.6
Percentage of women 76.4
Rheumatoid factor positive* 64.7 (1,433/2,213)
Anti-CCP antibodies positive 59.2 (1,333/2,251)
Erosions 53.1 (1,162/2,186)
Extra-articular manifestations† 24.7 (444/1,799)
Cardiovascular risk factors
Hypertension 37.9 (934/2,462)
Diabetes mellitus 12.5 (308/2,462)
Dyslipidemia 37.9 (935/2,462)
Obesity 21.2 (522/2,462)
Smoking habit 37.0 (911/2,462)
Patients with cardiovascular events 15.7 (410/2,609)
Ischemic heart disease 6.8 (179/2,609)
Heart failure 5.7 (149/2,609)
Cerebrovascular accident 4.5 (118/2,609)
Peripheral arteriopathy 1.9 (51/2,609)
Table 1.  Epidemiological and clinical characteristics of the 2,609 Spanish patients with rheumatoid 
arthritis included in the study. Anti-CCP antibodies: Anti-cyclic citrullinated peptide antibodies. *At least two 
determinations were required. †If patients experienced: nodular disease, Felty’s syndrome, pulmonary fibrosis, 
rheumatoid vasculitis, or secondary Sjögren’s syndrome.
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events or subclinical atherosclerosis in patients with RA (Table 3). In this regard, no significant differences were 
obtained when RA patients were stratified according to the presence/absence of CV events, after adjustment of 
the results for potential confounders (Table 3). It was also the case when RA patients were stratified according to 
the data derived from the evaluation of the cIMT and the presence/absence of carotid plaques, even after adjust-
ment (Table 3).
Discussion
Results from our study show that a large number of gene polymorphisms associated with CV disease or sub-
clinical atherosclerosis in the general population are not implicated in the increased risk or CV disease found in 
Caucasian individuals with RA, which is the prototype of chronic inflammatory rheumatic disease. Since a recent 
study that included a smaller series of North-American patients with RA found no association with CV disease 
of most of the gene polymorphisms assessed in our study, our results are also confirmatory and they further 
enhance the fact that the genetic predisposition for CV disease in RA may not be the same as that of the general 
population.
Similarities between atherosclerosis and chronic inflammatory diseases have been reported3. This is especially 
true for RA3,13. In this respect, recruitment of blood mononuclear cells, up-regulation of adhesion molecules and 
production of pro-inflammatory cytokines and matrix-degrading enzymes were described as potential common 
mechanisms involved in the initiation and perpetuation of both pathologies3. However, as pointed out before, a 
recent study performed in North-American patients with RA failed to demonstrate the implication of a series of 
pro-atherogenic genes, which were associated with CV disease in the general population, in the development of 
CVD in RA5.
According to our data, and in contrast to the general population4, TCF21, LPA, HHIPL1, RASD1-PEMT, 
MRPS6, CYP17A1-CNNM2-NT5C2, SMG6-SRR, PHACTR1, WDR12, COL4A1-COL4A2 polymorphisms are not 
associated with the development of CV events and the risk of subclinical atherosclerosis in patients with RA.
Change




Presence/absence of carotid 
plaques (n = 1,258)
P* OR (95% CI)* P† P‡ OR (95% CI)‡
TCF21 rs12190287 C/G 0.32 0.87 (0.66–1.14) 0.46 0.58 0.94 (0.77–1.15)
LPA rs3798220 T/C 0.15 1.90 (0.79–4.58) 0.14 0.52 1.23 (0.65–2.36)
HHIPL1 rs2895811 T/C 0.79 1.03 (0.79–1.35) 0.23 0.81 0.97 (0.79–1.19)
RASD1-PEMT rs12936587 G/A 0.53 1.08 (0.84–1.40) 0.56 0.43 1.08 (0.89–1.31)
MRPS6 rs9982601 C/T 0.73 1.07 (0.71–1.61) 0.53 0.59 0.92 (0.67–1.25)
CYP17A1-CNNM2-NT5C2 rs12413409 G/A 0.55 0.87 (0.56–1.36) 0.24 0.67 1.07 (0.78–1.48)
SMG6-SRR rs216172 G/C 0.85 0.97 (0.75–1.27) 0.14 0.31 0.90 (0.74–1.10)
PHACTR1 rs12526453 C/G 0.86 0.97 (0.74–1.27) 0.83 0.19 1.14 (0.93–1.39)
WDR12 rs6725887 T/C 0.16 1.28 (0.90–1.82) 0.08 0.24 0.85 (0.65–1.11)
COL4A1-COL4A2 rs4773144 A/G 0.93 1.01 (0.78–1.30) 0.89 0.62 0.95 (0.78–1.15)
Table 2.  Association between TCF21, LPA, HHIPL1, RASD1–PEMT, MRPS6, CYP17A1-CNNM2-NT5C2, 
SMG6-SRR, PHACTR1, WDR12 and COL4A1-COL4A2 polymorphisms and CV events or subclinical 
atherosclerosis in patients with RA. CV: cardiovascular; RA: rheumatoid arthritis; cIMT: carotid intima-media 
thickness; OR: odds ratio; CI: confidence interval. *Adjusted for sex, age at RA diagnosis, follow-up time and 
traditional CV risk factors using logistic regression. †Adjusted for sex, age at the time of ultrasonography study, 
follow-up time and traditional CV risk factors using analysis of covariance (ANCOVA). ‡Adjusted for sex, age at 
the time of ultrasonography study, follow-up time and traditional CV risk factors by logistic regression.
Change
Presence/absence of CV 
events (n = 2,609)
cIMT 
(n = 1,258)
Presence/absence of carotid 
plaques (n = 1,258)
P* OR (95% CI)* P† P‡ OR (95% CI)‡
ZHX2 rs11781551 G/A 0.96 1.00 (0.77–1.31) 0.37 0.24 0.88 (0.72–1.08)
PINX1 rs6601530 A/G 0.42 0.90 (0.69–1.16) 0.35 0.76 1.03 (0.85–1.25)
SLC17A4 rs4712972 G/A 0.07 1.41 (0.97–2.00) 0.99 0.98 0.99 (0.75–1.31)
LRIG1 rs17045031 G/A 0.72 1.12 (0.59–2.12) 0.35 0.42 0.81 (0.49–1.35)
LDLR rs6511720 G/T 0.25 0.81 (0.56–1.16) 0.08 0.46 1.10 (0.85–1.44)
Table 3.  Association between ZHX2, LRIG1, PINX1, SLC17A4 and LDLR polymorphisms and CV events 
or subclinical atherosclerosis in patients with RA. CV: cardiovascular; RA: rheumatoid arthritis; cIMT: 
carotid intima-media thickness; OR: odds ratio; CI: confidence interval. *Adjusted for sex, age at RA diagnosis, 
follow-up time and traditional CV risk factors using logistic regression. †Adjusted for sex, age at the time of 
ultrasonography study, follow-up time and traditional CV risk factors using analysis of covariance (ANCOVA). 
‡Adjusted for sex, age at the time of ultrasonography study, follow-up time and traditional CV risk factors by 
logistic regression.
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In our study, we also aimed to determine if other gene polymorphisms implicated in the increased risk of 
subclinical atherosclerosis in non-rheumatic Caucasians individuals6 could also influence the risk for CVD in 
RA. Unfortunately, unlike non-rheumatic Caucasians6, we did not disclose a relationship between ZHX2, PINX1, 
SLC17A4 2, LRIG1 and LDLR variants and CVD in patients with RA.
Taken together, our results suggest that RA itself should be considered an independent CV risk factor. 
Noteworthy, a former report from our group already highlighted genetic differences between the atherosclerosis 
disease in the general population and that associated to RA14. Consequently, our findings further support that the 
genetic component implicated in the development of atherosclerosis in RA may be different from that associated 
to “idiopathic” atherosclerosis. In this line, factors that are intrinsic to RA may independently contribute to the 
development of CVD.
In conclusion, our results do not confirm an association of TCF21, LPA, HHIPL1, RASD1-PEMT, MRPS6, 
CYP17A1-CNNM2-NT5C2, SMG6-SRR, PHACTR1, WDR12, COL4A1-COL4A2, ZHX2, PINX1, SLC17A4 2, 
LRIG1 and LDLR with CVD in patients with RA.
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